Research programme: JAK-STAT pathway inhibitors - CEAMEDAlternative Names: JAKINIB
Latest Information Update: 15 Jul 2016
At a glance
- Originator CEAMED
- Class Antineoplastics
- Mechanism of Action Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 15 Jul 2016 Early research in Cancer in Spain (unspecified route)